Kimmey M B
Division of Gastroenterology, University of Washington, Seattle 98195.
J Rheumatol Suppl. 1992 Nov;36:68-73.
The pathogenesis of nonsteroidal antiinflammatory drug (NSAID) induced gastrointestinal (GI) injury is complex and includes contributions from direct topical injury and reduced mucosal resistance due to indirect or systemic inhibition of mucosal prostaglandin (PG) synthesis. Some NSAID that cause less inhibition of gastroduodenal PG synthesis appear to cause less GI injury. NSAID induced GI complications include adverse symptoms, endoscopically observable mucosal damage, and ulcer complications. Ulcers are common in patients taking NSAID and are often asymptomatic; however, they may bleed or perforate. Prevention of GI complications can be approached by concomitant administration of a protective drug or by developing a safer NSAID. However, limitations of concomitant therapy with existing protective drugs suggest that new NSAID should be developed that are less harmful to the GI tract.
非甾体抗炎药(NSAID)引起胃肠道(GI)损伤的发病机制很复杂,包括直接局部损伤以及因间接或全身性抑制黏膜前列腺素(PG)合成导致的黏膜抵抗力降低。一些对胃十二指肠PG合成抑制作用较小的NSAID似乎引起的GI损伤也较少。NSAID引起的GI并发症包括不良症状、内镜下可观察到的黏膜损伤以及溃疡并发症。溃疡在服用NSAID的患者中很常见,且通常无症状;然而,它们可能会出血或穿孔。预防GI并发症可通过联合使用保护性药物或研发更安全的NSAID来实现。然而,现有保护性药物联合治疗的局限性表明,应研发对胃肠道危害较小的新型NSAID。